Key Points
- Insider sale: Oruka Therapeutics insider Joana Goncalves sold 7,000 shares on May 15 at an average price of $61.85, totaling $432,950. The sale was made under a pre-arranged Rule 10b5-1 plan.
- Stock and earnings update: The stock was down 3.1% and last traded around $61.93. Oruka recently reported a quarterly loss of $0.48 per share, beating analysts’ expectations of a $0.52 loss.
- Analyst outlook remains bullish: Multiple firms recently raised or reiterated strong price targets, and the consensus rating is Moderate Buy with an average target of $120.80. Institutional investors also hold a majority stake in the company at 56.44%.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $61.85, for a total value of $432,950.00. Following the transaction, the insider directly owned 33,377 shares in the company, valued at approximately $2,064,367.45. This represents a 17.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $66.12, for a total value of $462,840.00.
- On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The stock was sold at an average price of $40.91, for a total value of $312,593.31.
- On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $32.37, for a total value of $226,590.00.
Oruka Therapeutics Stock Down 3.1%
NASDAQ ORKA opened at $61.93 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $9.40 and a 52-week high of $91.00. The business's 50-day moving average price is $55.17 and its 200 day moving average price is $39.33. The firm has a market cap of $3.73 billion, a P/E ratio of -31.92 and a beta of -0.20.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.04. As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.2 earnings per share for the current year.
Institutional Investors Weigh In On Oruka Therapeutics
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the second quarter valued at about $28,000. BNP Paribas Financial Markets lifted its position in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada lifted its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 4th quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $39,000. Institutional investors and hedge funds own 56.44% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on ORKA. Wedbush set a $165.00 price target on Oruka Therapeutics in a report on Monday, April 27th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a "buy" rating in a research report on Monday, April 27th. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 16th. Finally, Barclays raised their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a research report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $120.80.
View Our Latest Stock Analysis on Oruka Therapeutics
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
